High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus

Clinical Endocrinology

Volumn 70, Issue 2, 2009, Pages 221-226

  Dullaart, Robin P F ^a   De Vries, Rindert ^a   Sluiter, Wim J ^a   Voorbij, Hieronymus A M ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIHYPERTENSIVE AGENT; ARYLDIALKYLPHOSPHATASE 1; BIGUANIDE DERIVATIVE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; INSULIN; LEPTIN; PHENOL; PHENYLACETIC ACID; RESISTIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYDROLYSIS; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADIPONECTIN; AGED; ARYLDIALKYLPHOSPHATASE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; LEPTIN; LINEAR MODELS; MALE; MIDDLE AGED; RESISTIN; RISK FACTORS;

EID: 58649124305     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03306.x     Document Type: Article

References (42)

1. Ross, R. (1999) Atherosclerosis-an inflammatory disease. New England Journal of Medicine, 340, 115 126.
2. Nyström, T. (2007) C-reactive protein: a marker or a player? Clinical Science, 113, 79 81.
3. Haffner, S.M. (2006) The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. American Journal of Cardiology, 97 (Suppl 3A 11A.
4. Schmidt, M.I. Duncan, B.B. (2003) Diabesity: an inflammatory metabolic condition. Clinical Chemistry and Laboratory Medicine, 41, 1120 1130.
5. Putz, D.M., Goldner, W.S., Bar, R.S. et al. (2004) Adiponectin and C-reactive protein in obesity, Type 2 diabetes, and monodrug therapy. Metabolism, 53, 1454 1461.
6. Dullaart, R.P., de Vries, R., van Tol, A. et al. (2007) Lower plasma adiponectin is a marker of increased intima-media thickness associated with type 2 diabetes mellitus and with male gender. European Journal of Endocrinology, 156, 387 384.
7. Linnemann, B., Voigt, W., Nobel, W. et al. (2006) C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome. Experimental Clinical Endocrinology and Diabetes, 114, 127 134.
8. Dullaart, R.P., de Vries, R., Dikkeschei, L.D. et al. (2007) Higher plasma leptin largely explains increased C-reactive protein levels in women. European Journal of Clinical Investigation, 37, 231 233.
9. Danesh, J., Whincup, P., Walker, M. et al. (2000) Low grade inflammation and coronary heart disease: prospective study and updated meta-analysis. British Medical Journal, 321, 199 204.
10. Dehghan, A., Kardys, I., de Maat, M.P. et al. (2007) Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes, 56, 872 878.
11. Nofer, J.R., Kehrel, B., Fobker, M. et al. (2002) HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis, 161, 1 16.
12. Kontush, A. Chapman, M.J. (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacological Reviews, 58, 342 374.
13. Saito, M., Ishimitsu, T., Minami, J. et al. (2003) Relations of plasma high-sensitive C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis, 167, 73 79.
14. Mackness, M., Durrington, P. Mackness, B. (2004) Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Current Opinion in Lipidology, 15 James, R.W. (2000) Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arteriosclerosis, Thrombosis and Vascular Biology, 20, 516 521.
15. Mackness, B., Davies, G.K., Turkie, W. et al. (2001) Paraoxonase status in coronary heart disease. Are activity and concentration more important than genotype? Arteriosclerosis, Thrombosis and Vascular Biology, 21, 1451 1457.
16. Mastorikou, M., Mackness, M. Mackness, B. (2006) Defective metabolism of oxidized phospholipids by HDL from people with type 2 diabetes. Diabetes, 55, 3096 3103.
17. Watson, A.D., Berliner, J.A., Hama, S.Y. et al. (1995) Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity and minimally oxidized low density lipoprotein. Journal of Clinical Investigation, 96, 2882 2891.
18. Mackness, B., Hine, D., Liu, Y. et al. (2004) Paraoxonase 1 inhibits oxidised LDL induced MCP-1 protection by endothelial cells. Biochemical and Biophysical Research Communications, 318, 680 683.
19. Mackness, B., Mackness, M.I., Arrol, S. et al. (1998) Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis, 139, 341 349.
20. Inoue, M., Suehiro, T., Nakamura, T. et al. (2000) Serum arylesterase/diazonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism, 49, 1400 1405.
21. Hedrick, C.C., Thorpe, S.R., Fu, M.X. et al. (2000) Glycation impairs high-density lipoprotein function. Diabetologia, 43, 312 320.
22. Kalmár, T., Seres, I., Balogh, Z. et al. (2005) Correlation between the activities of lipoprotein lipase and paraoxonase in type 2 diabetes mellitus. Diabetes and Metabolism, 31, 574 580.
23. Gugliucci, A., Hermo, R., Tsuji, M. et al. (2006) Lower serum paraoxonase-I activity in type 2 diabetic patients correlates with nitrated apolipoprotein A-I levels. Clinica Chimica Acta, 368, 201 202.
24. Mackness, B., Hine, D., McElduff, P. et al. (2006) High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis, 186, 396 401.
25. van Himbergen, T.M., Roest, M., de Graaf, J. et al. (2005) Indications that paraoxonase-1 contributes to high density lipoprotein levels in familial hypercholesterolemia. Journal of Lipid Research, 46, 445 451.
26. Ronti, T. Mannarino, E. (2006) The endocrine function of adipose tissue: an update. Clinical Endocrinology, 64, 355 365.
27. Ouchi, N., Kihara, S., Funahashi, T. et al. (2003) Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation, 107, 671 674.
28. Shetty, G.K., Economides, P.A., Horton, E.S. et al. (2004) Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care, 27, 2450 2457.
29. Ble, A., Windham, B.G., Bandinelli, S. et al. (2005) Relation of plasma leptin to C-reactive protein in older adults (from the Invecchiare nel Chianti study). America Journal of Cardiology, 96, 991 995.
30. Beltowski, J. (2006) Leptin and atherosclerosis. Atherosclerosis, 189, 47 60.
31. Matthews, D.R., Hosker, J.P., Rudenski, A.S. et al. (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412 419.
32. Liu, M.Y., Xydakis, A.M., Hoogeveen, R.C. et al. (2005) Multiplexed analysis of biomarkers and the metabolic syndrome in human plasma, using the Luminex-100 system. Clinical Chemistry, 51, 1102 1109.
33. Klamer, A., Skogstrand, K., Hougaard, D.M. et al. (2007) Adiponectin levels measured in dried blood spot samples from neonates born small and appropriate for gestational age. European Journal of Endocrinology, 157, 189 194.
34. Nevin, D.N., Zambon, A., Furlong, C.E. et al. (1996) Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arteriosclerosis, Thrombosis and Vascular Biology, 16, 1243 1249.
35. Roest, M., van Himbergen, T.M., Barendrecht, A.B. et al. (2007) Genetic and environmental determinants of the PON-I phenotype. European Journal of Clinical Investigation, 37, 187 196.
36. Beltowski, J., Wojcicka, G. Jamroz, A. (2003) Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis, 170, 21 29.
37. De Vries, R., Wolffenbuttel, B.H., Sluiter, W.J. et al. (2005) Post-heparin plasma lipoprotein lipase, but not hepatic lipase activity, is related to plasma adiponectin in type 2 diabetic patients and healthy subjects. Clinical Laboratory, 51, 403 409.
38. Matsuura, F., Oku, H., Koseki, M. et al. (2007) Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochemical and Biophysical Research Communications, 358, 1091 1095.
39. Vergès, B., Petit, J.M., Duvillard, L. et al. (2006) Adiponectin is an important determinant of apo A-I catabolism. Arteriosclerosis, Thrombosis and Vascular Biology, 26, 1364 1369.
40. Bajnok, L., Seres, I., Varga, Z. et al. (2007) Relationship of endogenous hyperleptinemia to serum paraoxonase 1, cholesteryl ester transfer protein, and lecithin cholesterol acyltransferase in obese individuals. Metabolism, 56, 1542 1549.
41. Bajnok, L., Csongradi, E., Seres, I. et al. (2008) Relationship of adiponectin to serum paraoxonase 1. Atherosclerosis, 197, 363 367.
42. Feingold, K.R., Memon, R.A., Moser, A.H. et al. (1998) Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis, 139, 307 315.